Changes in d2b3c29: more fixes

				BL_genes.md
			
          @@ -101,7 +101,7 @@ link-citations: true

           |[MYO18A](MYO18A)|Tier 2 GE[@schmitzBurkittLymphomaPathogenesis2012]|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)|||

           |[NBEAL1](NBEAL1)|Tier 2 GE[@loveGeneticLandscapeMutations2012]|[Love et al](papers/loveGeneticLandscapeMutations2012)||PASS|

           |[NCOR2](NCOR2)|Tier 2 GE[@schmitzBurkittLymphomaPathogenesis2012]|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)|[@sarkozyMutationalLandscapeGray2021; @spinaGeneticsNodalMarginal2016]||

          -|[NOA1](NOA1)|Tier 2 GE[@burkhardtClinicalRelevanceMolecular2022b]|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022b)|||

          +|[NOA1](NOA1)|Tier 2 GE[@burkhardtClinicalRelevanceMolecular2022]|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|||

           |[P2RY2](P2RY2)|Tier 2 GE[@loveGeneticLandscapeMutations2012]|[Love et al](papers/loveGeneticLandscapeMutations2012)||PASS|

           |[PDCD11](PDCD11)|Tier 2 GE[@schmitzBurkittLymphomaPathogenesis2012]|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)|||

           |[PIM1](PIM1)|Tier 2 GE[@burkhardtClinicalRelevanceMolecular2022], FE[@kuoRolePIM1Ibrutinibresistant2016], aSHM|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|[@drevalGeneticSubdivisionsFollicular2023; @dunsCharacterizationDLBCLPMBL2021; @pasqualucciHypermutationMultipleProtooncogenes2001]||

...	...	@@ -101,7 +101,7 @@ link-citations: true
101	101	\|[MYO18A](MYO18A)\|Tier 2 GE[@schmitzBurkittLymphomaPathogenesis2012]\|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)\|\|\|
102	102	\|[NBEAL1](NBEAL1)\|Tier 2 GE[@loveGeneticLandscapeMutations2012]\|[Love et al](papers/loveGeneticLandscapeMutations2012)\|\|PASS\|
103	103	\|[NCOR2](NCOR2)\|Tier 2 GE[@schmitzBurkittLymphomaPathogenesis2012]\|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)\|[@sarkozyMutationalLandscapeGray2021; @spinaGeneticsNodalMarginal2016]\|\|
104		-\|[NOA1](NOA1)\|Tier 2 GE[@burkhardtClinicalRelevanceMolecular2022b]\|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022b)\|\|\|
	104	+\|[NOA1](NOA1)\|Tier 2 GE[@burkhardtClinicalRelevanceMolecular2022]\|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)\|\|\|
105	105	\|[P2RY2](P2RY2)\|Tier 2 GE[@loveGeneticLandscapeMutations2012]\|[Love et al](papers/loveGeneticLandscapeMutations2012)\|\|PASS\|
106	106	\|[PDCD11](PDCD11)\|Tier 2 GE[@schmitzBurkittLymphomaPathogenesis2012]\|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)\|\|\|
107	107	\|[PIM1](PIM1)\|Tier 2 GE[@burkhardtClinicalRelevanceMolecular2022], FE[@kuoRolePIM1Ibrutinibresistant2016], aSHM\|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)\|[@drevalGeneticSubdivisionsFollicular2023; @dunsCharacterizationDLBCLPMBL2021; @pasqualucciHypermutationMultipleProtooncogenes2001]\|\|